Literature DB >> 29273105

The Utility and Validity of the Alopecia Areata Symptom Impact Scale in Measuring Disease-Related Symptoms and their Effect on Functioning.

Tito R Mendoza1, Joyce Osei2, Madeleine Duvic2.   

Abstract

Alopecia areata (AA) is an autoimmune disease that causes hair loss. Although persons with the disease can be physically described as having varying degrees of hair loss, the condition has significant ramifications on an individual's well-being. We previously reported the preliminary psychometric properties of the Alopecia Areata Symptom Impact Scale (AASIS), a disease-specific measure that asks participants about their AA symptoms and how these symptoms interfere with their daily functioning. The goals of this article are to provide a detailed description of the development of the AASIS items and to offer a psychometric update for the measure. Preliminary items for the AASIS were developed on the basis of responses from 1,649 participants to 125 health-related quality-of-life questions/items from the National Alopecia Areata Registry. Clinicians affiliated with the registry were asked to rate the relevance of these items for content validity. Cluster analysis and clinician ratings were used to reduce the number of items. The resulting 13-item AASIS was administered to 452 participants, who were also cognitively debriefed. Results showed that the AASIS is a valid and reliable measure of AA symptoms and their impact on functioning.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29273105     DOI: 10.1016/j.jisp.2017.10.009

Source DB:  PubMed          Journal:  J Investig Dermatol Symp Proc        ISSN: 1087-0024


  4 in total

1.  Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review.

Authors:  Atrin Toussi; Virginia R Barton; Stephanie T Le; Oma N Agbai; Maija Kiuru
Journal:  J Am Acad Dermatol       Date:  2020-06-17       Impact factor: 15.487

Review 2.  Defining Severity in Alopecia Areata: Current Perspectives and a Multidimensional Framework.

Authors:  Brett A King; Maryanne M Senna; Manabu Ohyama; Antonella Tosti; Rodney D Sinclair; Susan Ball; Justin M Ko; Marc Glashofer; Rodrigo Pirmez; Jerry Shapiro
Journal:  Dermatol Ther (Heidelb)       Date:  2022-03-31

3.  Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib.

Authors:  R Winnette; A Banerjee; V Sikirica; E Peeva; K Wyrwich
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-01-25       Impact factor: 9.228

Review 4.  Measuring Patient Quality of Life Following Treatment for Alopecia.

Authors:  Kunlawat Thadanipon; Poonkiat Suchonwanit
Journal:  Patient Prefer Adherence       Date:  2021-07-16       Impact factor: 2.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.